Drugs equivalent in angina treatment: study
Posted on: Tuesday, 22 November 2005, 16:13 CST
CHICAGO (Reuters) - The blood-thinning drug Lovenox works as well as a standard artery-clearing drug in patients with severe heart-related chest pain, but neither reduced the risk of death after a year of treatment, a study said on Tuesday.
The research, paid for by Aventis Pharmaceuticals, a member of the Sanofi-Aventis Group which makes Lovenox, involved nearly 10,000 patients at 487 hospitals in 12 countries who suffered from acute coronary syndromes -- severe angina that cannot be treated with surgery or angioplasty.
They had undergone revascularization, a treatment in which small holes are laser-drilled in the heart tissue to improve blood flow.
In the study, which covered a year, the patients were treated with either enoxaparin, the generic name for Lovenox, or a form of heparin, the standard medicine used in many hospitals for artery-clearing.
After one year the death rates in the two treatment groups were similar, said the report from the Duke Clinical Research Institute, in Durham, North Carolina.
"High-risk patients with acute coronary syndromes remain susceptible to continued cardiac events despite aggressive therapies," concluded the report published in this week's Journal of the American Medical Association.
Source: REUTERS
Related Articles
- Repligen Announces Completion of Patient Treatment in Phase 3 Clinical Trial of RG1068 in MRI Imaging of the Pancreas
- Oculus Completes Patient Treatment in Phase II Diabetic Foot Ulcer Trial
- Oculus Innovative Sciences Completes Patient Treatment and Follow-Up in Its Phase II Clinical Trial in Mildly Infected Diabetic Foot Ulcers
- Patient Treatment for Bipolar Disorder Varies Depending on Doctor Specialty; Well Designed Clinical Trials May Be The Answer
- USNS Comfort Conducts 55,465 Patient Treatments in First Month
- Viventia Initiates Patient Treatment in Bladder Cancer Trial
- Work Starts on ASH's List of Repairs: Recent Analysis Showed Breakdowns in Patient Treatment
- New Blood Test Helps Personalize Patients' Treatment
- Patient Treatment Initiated in ADVENTRX International Phase IIb Metastatic Colorectal Cancer Trial
- ImClone Systems Commences Patient Treatment in U.S. Phase I Clinical Trial Of IMC-1121B
 |
 |
User Comments (0)
RSS Feeds